Amarin Corp Plc (AMRN)

[Biobillionair]

Copy of full Appeals Docket:

08/03/2020 1
17 pg, 3.12 MB Appeal docketed. Received: 07/27/2020. [711836]
Entry of Appearance is due on 08/17/2020. Certificate of Interest is due on 08/17/2020. Docketing Statement is due on 08/17/2020. Appellant's brief is due on 10/02/2020. [KMH] [Entered: 08/03/2020 11:20 AM]
08/06/2020 2
2 pg, 258.28 KB Entry of appearance for Jonathan E. Singer; Deanna J. Reichel; Nitika Gupta Fiorella; Oliver Richards; Eric Sonnenschein; Jeffrey Elikan; Christopher Sipes as counsel for Appellants Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited. Service: 08/06/2020 by email. [713105] [20-2108] [Jonathan Singer] [Entered: 08/06/2020 03:20 PM]
08/06/2020 3
4 pg, 128.9 KB Certificate of Interest for Appellants Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited. Service: 08/06/2020 by email. [713107] [20-2108] [Jonathan Singer] [Entered: 08/06/2020 03:23 PM]
08/06/2020 4
2 pg, 457.96 KB Docketing Statement for the Appellants Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited. Service: 08/06/2020 by email. [713111] [20-2108] [Jonathan Singer] [Entered: 08/06/2020 03:25 PM]
08/06/2020 5
2 pg, 200.06 KB Entry of appearance for Charles B. Klein; Eimeric Reig-Plessis; Claire A. Fundakowski; Alison M. Heydorn as counsel for Appellees Hikma Pharmaceuticals USA Inc. and Hikma Pharmaceuticals International Limited. Service: 08/06/2020 by email. [713140] [20-2108] [Charles Klein] [Entered: 08/06/2020 04:23 PM]
08/06/2020 6
2 pg, 396.51 KB Docketing Statement for the Appellees Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA Inc.. Service: 08/06/2020 by email. [713145] [20-2108] [Charles Klein] [Entered: 08/06/2020 04:28 PM]
08/06/2020 7
3 pg, 143.04 KB Certificate of Interest for Appellees Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA Inc.. Service: 08/06/2020 by email. [713146] [20-2108] [Charles Klein] [Entered: 08/06/2020 04:31 PM]
08/11/2020 8
13 pg, 350.38 KB MOTION of Appellants Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited and Appellees Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA Inc. to consolidate appeals (20-1723) [Consent: unopposed]. Service: 08/11/2020 by email. [714224] [20-2108] This document is non-compliant. See Doc No. [9] [Deanna Reichel] [Entered: 08/11/2020 02:53 PM]
08/12/2020 9
1 pg, 120.78 KB NOTICE OF NON-COMPLIANCE: The submission of Appellants Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited and Appellees Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA Inc., Motion to consolidate appeals [8], is not in compliance with the rules of this court (see attached). Compliant document due on 08/19/2020. Service as of this date by the Clerk of Court. [714370] [KMH] [Entered: 08/12/2020 10:11 AM]
08/12/2020 10
15 pg, 382.6 KB MOTION of Appellants Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited and Appellees Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA Inc. to consolidate appeals (20-1723) [Consent: unopposed]. Service: 08/12/2020 by email. [714411] [20-2108] [Deanna Reichel] [Entered: 08/12/2020 12:39 PM]
08/12/2020 11
21 pg, 603.26 KB MOTION of Appellants Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited and Appellees Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA Inc. to consolidate appeals (20-1723) [Consent: unopposed]. Service: 08/12/2020 by email. [714414] [20-2108] [Deanna Reichel] [Entered: 08/12/2020 12:49 PM]

MOTION of Appellants Amarin Pharma, Inc., Amarin Pharmaceuticals Ireland Limited and Appellees Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA Inc. to consolidate appeals (20-1723)


While this motion is likely to be granted I can come up with reasons why it shouldn’t be granted. #1 Would be Composition patent that is due to be placed in OB with August/September update. Direct infringement is open and closed with Judge Du’s original verdict. Why should the Appeals court split hairs at oral arguments when there’s no way in hell generics can launch free of risk with or without the courts intervention. If court sides with Du and upholds Du’s infringement block generics. If Du is overturned, generics still cannot launch free of risk.

Patent that stops generics regardless of Appeals court ruling:

10,722,485
Osterloh , et al. July 28, 2020

Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy

Abstract
In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

I understand why Amarin wants a clean record on patents, but it’s not necessary to get a business deal done now.

BB